Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NAUTILUS BIOTECHNOLOGY, INC.

(NAUT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nautilus Biotechnology, Inc.(NasdaqGS:NAUT) added to S&P TMI Index

09/20/2021 | 12:00am EST

Nautilus Biotechnology, Inc.(NasdaqGS:NAUT) added to S&P TMI Index


ę S&P Capital IQ 2021
All news about NAUTILUS BIOTECHNOLOGY, INC.
11/02NAUTILUS BIOTECHNOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
11/02Nautilus Biotechnology Posts Narrower Q3 Loss
MT
11/02Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Prot..
GL
11/02Cowen Initiates Coverage on Nautilus Biotechnology With Outperform Rating
MT
11/02Nautilus Biotechnology Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/02NAUTILUS BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/02Nautilus Biotechnology Reports Third Quarter 2021 Financial Results
GL
11/02Nautilus Biotechnology Reports Third Quarter 2021 Financial Results
GL
10/11NAUTILUS BIOTECHNOLOGY : to Announce Third Quarter of Fiscal Year 2021 Financial Results o..
AQ
09/20NAUTILUS BIOTECHNOLOGY, INC.(NASDAQG : NAUT) added to S&P TMI Index
CI
More news
Analyst Recommendations on NAUTILUS BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -50,3 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -6,53x
Yield 2021 -
Capitalization 567 M 567 M -
EV / Sales 2021 -
EV / Sales 2022 121x
Nbr of Employees 97
Free-Float 62,0%
Chart NAUTILUS BIOTECHNOLOGY, INC.
Duration : Period :
Nautilus Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NAUTILUS BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,57 $
Average target price 11,50 $
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Sujal M. Patel President, CEO, Secretary & Director
Anna Mowry Chief Financial Officer & Treasurer
Parag Mallick Director & Chief Scientist
Mary E. Godwin Vice President-Operations
Michael R. Altman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NAUTILUS BIOTECHNOLOGY, INC.-57.88%567
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-40.81%24 321